not clear to me this is value driven rally, but good news for regeneron. to merck, i'm not as big a fan of merck. lilly hat biggest pipe. but see if regeneron can break the spell of negativity over biotech. >> they benefit from lilly stumbling. >> now they have clearfield with am j amgen. >> cell gene would be up five if it wasn't for the fact that there is this pull on biotech. watch cell gene, amgen and regeneron. >> we have the opening bell coming up for this monday. stay with us. my name is mark amann. i'm a gas service rep for pg&e in san jose. as a gas service rep we are basically the ambassador of the company. we make the most contact with the customers on a daily basis. i work hand-in-hand with crews to make sure our gas pipes are safe. my wife and i are both from san jose. my kids and their friends live in this community. every time i go to a customer's house, their children could be friends with my children so it's important to me. one of the most rewarding parts of this job is after you help a customer, seeing a smile on their face. together, we

those include regeneron and amgen. they're the big players there with recently approved injectable drugs that lower the bad cholesterol in patients who don't respond to perian is deve form. in tech, it's fairly flat, fairly mixed. nxp higher. activision ahead of the holidays and facebook with its new buy button that it's going to have in its feed. back to you. >> all right. bertha, thank you very much. americans are slowly starting to believe that lower gas prices are here to stay and that's one of the findings in cnbc's periodic all america economic survey. steve liesman here to break it down for us. i can see on the chart that you're going to tell us what people are doing or say they are doing -- >> say they are doing. it's all we can do right now. but we've continued to use the survey to get at this critical question for the u.s. economy. what's been happening to the savings from gasoline, and we've asked this several times. what we see here is a little loosening up. not all the way, not what you'd expect. let's go

we see gains in drugmakers like regeneron and amgen because of the bad news in eli lilly.y stopped trials for cholesterol drug. it has also hampered the other efforts of drugmakers trying to come up with a drug to reduce good cholesterol while reducing bad cholesterol. regeneron, amgen, they make a cholesterolass of drugs, which will continue to be selling well as long as the other drugs do not come out. those companies are doing well today. over here, green mountain coffee roasters. the curate stock is not -- keurig stock is not doing well. ordoes not like cyclicals keurig coffee. betty: thank you so much. speaking about make your own ,rinks -- still ahead controversy is apparently good for business in the world of daily fantasy sports. and fanduel have posted their best weekend ever. more on their $44 million taking this weekend. ♪ betty: welcome back to the "bloomberg market day." it was a thrill of a weekend for you football fans cap. by this moment last night. the giants against the 49ers. 1:49 to go. the 49ers score to take the lead. eli manning then with the perfect

initially that stock rose as well as the others from amgen and regeneron sanofi because folks thought it would lessen the competitive landscape. but as the day went on that stock fell as folks started to worry that company would need to do what are more known as outcome studies before getting approval of this drug. because this market is so big, mltz of patients in the united states, billions of dollars at stake, a lot of stocks moving on this big negative surprise from ely lilly. for "nightly business report" i'm meg tirrell. >>> ferrari is getting ready to offer shares to the public. today fiat chrysler announced the launch of its ferrari spinoff and that it plans to sell a nearly 9% stake in the automaker in its initial public offering. the shares will price between $48 and $52. and will raise about a billion from investors. shares will trade on the new york stock exchange under the very apt ticker symbol race. >>> meantime, standard & poor's downgrading volkswagen's credit rating citing the emissions scandal. the automaker's short-term corporate credit rating was cut to a-minus fr

2025 and where does that money go and my thinking it would go to the canine drug makers am gen and regeneron, which popped in advance of what happened. >> and listen to what pete said about valuation. eli lilly is 42 times forward earnings. and you just mentioned am gen and i'll piggy back there. and this trades 13.5 to 14 times forward earnings. does am gen win? yes. but it should trade any way. and it did hold the level. so if you want to trade it on the long side, you do it like he just said. >>> today downgrading buffalo wild wings and dine equity and others. they are basically saying, the jobs numbers and the pmi numbers are not that great and even though consumers are saving on fuel, that is not enough. >> and what do you do inside of this space. the casual dining versus fast food, it has outperformed. and it was passed on to custs -- customers that were happy to do it. and if you look at that sector, the buffalo wild wings, all of them traded, 30, 35, 40 times earnings and that is a problem. i continue to go back to mcdonald's. i think in the value fast food space and even yum, that w

regeneron returned as di brmn. got hammered after that great interview we had with ceo jj it was in days of yore monday. now it's up $12 from the bottom a couple days ago. or look at radius vaulting more than 21%, why? nothing. no news whatsoever. the company's bone dead drug nothing new. biotech's back. my terrible trust has been buying biogen declining from $480 in march down to $254 earlier this morning. roared higher only close up to more than 11 smackers. that's no coincidence. it's a sign of growth, love, desperation. within investors looking for it wherever it can possibly be found right now.seh, or even in the future. the hunt, it is on. second, people are flocking to the internet stocks again. yes, the internet. it has been a -- >> the house of pain! >> -- for anyone who entered lately, more like an apartment complex.itckee o epa google supposed to be a new favorite after broke itself into alphabets began to trade like alphabet soup no insult meant to campbell's. you see facebook? it's hard to call a stock

amgen me, regeneron and are doing well today because eli lilly is doing poorly. ay pulling its bad cholesterol deter but good cholesterol enhancer. it was not effective enough. merck had a similar drug that may also not be effective. it is only in phase three. that is benefiting competitors that have drugs that are proven effective in beating bad cholesterol. there is a note out, it talked about the cyclicals gaining over the last week. also heof the rise but lists a bunch of stocks that have no cash positions and weak cash flow on equity. keurig,cludes green mountain coffee roasters not today. let's take a look at the european close. the six-dayover, rise in european stocks, the longest since july, has ended. the stoxx 600, 39 minutes after the session began. investors are pondering the next move in u.s. interest rates and hoping for more stimulus from china. the ftse 100 snapping an eight-day winning streak. mining shares ending their longest run since 2000. dave rose for nine consecutive days and added 26% or 45 billion euros. it is over. i can say that many t

celgene, regeneron, even myelin which has tried so far unsuccessfully to take off peridot. oscina health is up. other healthcare it services, all scripts also higher today. liberty global which is in talks to potentially acquire wireless communications that's higher today. media stocks, dream works, viacom, discovery also soaring. check out the gaming stocks, the wynn resorts it is one of the nasdaq 100s top performers today. even though they don't trade here i would mention las vegas and mgm resorts are all up big today and that's presumably on that surprise cut in china and what that could mean for macau. >> we will talk to boyd gaming next hour. >>> take a look at facebook trading over $100 a share, brand-new record for the stock three years in the making up 170% since it's ipo way back in may of 2012. but is this the top? >> let's bring in max wolf from manhattan venture partners. max, welcome. always a pleasure, thanks for having me. >> kelly asked the question in the intro is it the top? is it fully valued or not? >> near term we are probably at or close to a top. we